UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.029

Sortiert nach

ANÁLISE DO PERFIL EPIDEMIOLÓGICO E DA EFICÁCIA DO USO DA TERAPIA DUPLA EM PACIENTES HIV DO AMBULATÓRIO DE INFECTOLOGIA DO HOSPITAL SANTA CASA DE MISERICÓRDIA DE VITÓRIA/ES

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102976, Article 102976

2023

Volltextzugriff (PDF)

MEDICINE AND THE LAW

South African medical journal, 2022-10, Vol.112 (10)

2022

Volltextzugriff (PDF)

RESISTÊNCIA AO DOLUTEGRAVIR EM UM CASO DE TRANSMISSÃO VERTICAL

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103051

2023

Volltextzugriff (PDF)

SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV NA BAHIA: DADOS DE VIDA REAL

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103055

2023

Volltextzugriff (PDF)

Camino a una licencia obligatoria para el dolutegravir en Colombia

Salud UIS, 2023, Vol.55 (1)

Rossi, Francisco

2023

Volltextzugriff (PDF)

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología, 2023-05, Vol.43 (3), p.370-373

2023

Volltextzugriff (PDF)

Synthesis and characterization of two known and one new impurities of dolutegravir: In silico evaluation of certain intermediates against SARS CoV-2 O-ribose methyltransferase (OMTase)

Journal of molecular structure, 2023-01, Vol.1271, p.133992-133992, Article 133992

2023

Volltextzugriff (PDF)

Investigation of Levan-Derived Nanoparticles of Dolutegravir: A Promising Approach for the Delivery of Anti-HIV Drug as Milk Admixture

Journal of pharmaceutical sciences, 2024-08, Vol.113 (8), p.2513-2523

2024

Volltextzugriff (PDF)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical infectious diseases, 2021-07, Vol.73 (2), p.e485-e493

2021

Volltextzugriff (PDF)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

AIDS (London), 2021-10, Vol.35 (12), p.1957-1965

2021

Volltextzugriff (PDF)

Central nervous system and neuropsychiatric disturbances in people living with HIV

Le infezioni in medicina, 2023, Vol.31 (4)

2023

Volltextzugriff (PDF)

regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa

Pharmacogenomics, 2021-09, Vol.22 (15), p.963-972

2021

Volltextzugriff (PDF)

Outcomes of Dolutegravir-Based Antiretroviral Therapy in Thai Youth Aged 18 to 24 Years Living with HIV in Bangkok: A Retrospective Cohort Study

Journal of the Medical Association of Thailand, 2023-10, Vol.106 (10), p.932-942

2023

Volltextzugriff (PDF)

PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103038

2023

Volltextzugriff (PDF)

ADESÃO EM INDIVÍDUOS COM FALHA VIROLÓGICA INICIAL EM PESSOAS VIVENDO COM HIV QUE INICIARAM A TERAPIA ANTIRRETROVIRAL – COORTE RETROSPECTIVA, BRASIL 2017-2019 (DADOS PRELIMINARES)

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102967

2023

Volltextzugriff (PDF)

ALTERAÇÃO NO ÍNDICE DE MASSA CORPÓREA (IMC) APÓS SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV ATENDIDOS EM UM SERVIÇO ESPECIALIZADO DE SALVADOR, BAHIA

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102972

2023

Volltextzugriff (PDF)

Real world use of dolutegravir two drug regimens

AIDS (London), 2023-04, Vol.37 (5), p.785-788

2023

Volltextzugriff (PDF)

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy

Clinical infectious diseases, 2020-12, Vol.71 (9), p.e471-e477

2020

Volltextzugriff (PDF)

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

AIDS (London), 2023-11, Vol.37 (14), p.2131

2023

Volltextzugriff (PDF)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen

AIDS (London), 2021-07, Vol.35 (9), p.1423-1432

2021

Volltextzugriff (PDF)

Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection

Mediterranean journal of infection, microbes & antimicrobials, 2022-12, Vol.11 (1)

2022

Volltextzugriff (PDF)

Adverse drug reactions, adherence, and virologic outcomes in adult patients on dolutegravir- based antiretroviral therapy at a tertiary hospital, southeast Nigeria

Ghana medical journal, 2024-03, Vol.58 (1), p.101-108

2024

Volltextzugriff (PDF)

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Clinical infectious diseases, 2019-10, Vol.69 (9), p.1498-1505

2019

Volltextzugriff (PDF)

Identification and simultaneous quantification of potential genotoxic impurities in first-line HIV drug dolutegravir sodium using fast ultrasonication-assisted extraction method coupled with GC–MS and in-silico toxicity assessment

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-09, Vol.1245, p.124275, Article 124275

2024

Volltextzugriff (PDF)

Control over selectivity for demethylation in dolutegravir synthesis in microreactors: Kinetics and mechanisms

Chemical engineering science, 2024-02, Vol.284, p.119453, Article 119453

2024

Volltextzugriff (PDF)

1 – 25 von 1.029

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(902)
Mit Volltextzugriff
(840)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Dolutegravir
(954)
Science & Technology
(825)
Life Sciences & Biomedicine
(776)
Hiv
(612)
Infectious Diseases
(453)
Humans
(443)
Human Immunodeficiency Virus
(379)
Hiv Infections - Drug Therapy
(370)
Immunology
(276)
Antiretroviral Drugs
(259)
Antiretroviral Therapy
(236)
Female
(208)
Antiretroviral Agents
(198)
Drug Therapy
(196)
Pharmacology & Pharmacy
(188)
Male
(184)
Adult
(178)
Highly Active Antiretroviral Therapy
(156)
Heterocyclic Compounds, 3-Ring - Therapeutic Use
(153)
Virology
(152)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

ANÁLISE DO PERFIL EPIDEMIOLÓGICO E DA EFICÁCIA DO USO DA TERAPIA DUPLA EM PACIENTES HIV DO AMBULATÓRIO DE INFECTOLOGIA DO HOSPITAL SANTA CASA DE MISERICÓRDIA DE VITÓRIA/ES

MEDICINE AND THE LAW

RESISTÊNCIA AO DOLUTEGRAVIR EM UM CASO DE TRANSMISSÃO VERTICAL

SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV NA BAHIA: DADOS DE VIDA REAL

Camino a una licencia obligatoria para el dolutegravir en Colombia

Acute interstitial nephritis due to dolutegravir: The first case reported

Synthesis and characterization of two known and one new impurities of dolutegravir: In silico evaluation of certain intermediates against SARS CoV-2 O-ribose methyltransferase (OMTase)

Investigation of Levan-Derived Nanoparticles of Dolutegravir: A Promising Approach for the Delivery of Anti-HIV Drug as Milk Admixture

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

Central nervous system and neuropsychiatric disturbances in people living with HIV

regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa

Outcomes of Dolutegravir-Based Antiretroviral Therapy in Thai Youth Aged 18 to 24 Years Living with HIV in Bangkok: A Retrospective Cohort Study

PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL

ADESÃO EM INDIVÍDUOS COM FALHA VIROLÓGICA INICIAL EM PESSOAS VIVENDO COM HIV QUE INICIARAM A TERAPIA ANTIRRETROVIRAL – COORTE RETROSPECTIVA, BRASIL 2017-2019 (DADOS PRELIMINARES)

ALTERAÇÃO NO ÍNDICE DE MASSA CORPÓREA (IMC) APÓS SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV ATENDIDOS EM UM SERVIÇO ESPECIALIZADO DE SALVADOR, BAHIA

Real world use of dolutegravir two drug regimens

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen

Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection

Adverse drug reactions, adherence, and virologic outcomes in adult patients on dolutegravir- based antiretroviral therapy at a tertiary hospital, southeast Nigeria

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Identification and simultaneous quantification of potential genotoxic impurities in first-line HIV drug dolutegravir sodium using fast ultrasonication-assisted extraction method coupled with GC–MS and in-silico toxicity assessment

Control over selectivity for demethylation in dolutegravir synthesis in microreactors: Kinetics and mechanisms

Suchergebnisse filtern